EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

PSTPIP1-Associated Myeloid-Related Proteinemia Inflammatory (PAMI) Syndrome: A Systematic Review

Manel Mejbri iD, Raffaele Renella, Fabio Candotti, Cecile Jaques iD, Dirk Holzinger iD, Michael Hofer, Katerina Theodoropoulou

Genes · 19.08.2023 · 14 (8) · 1655

DOI: 10.3390/genes14081655 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Genes, online erschienen am 19.08.2023. Verfasst von Manel Mejbri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Immuno-Rheumatology of Western Switzerland, Department Women-Mother-Child, Lausanne University Hospital and University of Lausanne, 1011 La…. Hauptthemen laut MEDLINE: Tumor Necrosis Factor Inhibitors, Neutropenia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PSTPIP1 (proline-serine-threonine phosphatase-interactive protein 1)-associated myeloid-related proteinemia inflammatory (PAMI) syndrome, previously known as Hyperzincemia/Hypercalprotectinemia (Hz/Hc) syndrome, is a recently described, rare auto-inflammatory disorder caused by specific deleterious variants in the PSTPIP1 gene (p.E250K and p.E257K). The disease is characterized by chronic systemic inflammation, cutaneous and osteoarticular manifestations, hepatosplenomegaly, anemia, and neutropenia. Increased blood levels of MRP 8/14 and zinc distinguish this condition from other PSTPIP1-associated inflammatory diseases (PAID). The aim of this systematic review is to provide a comprehensive overview of the disease phenotype, course, treatment, and outcome based on reported cases. This systematic review adheres to the PRISMA guidelines (2020) for reporting. A literature search was performed in Embase, Medline, and Web of Science on 13 October 2022. The quality of the case reports and case series was assessed using the JBI checklists. Out of the 43 included patients with PAMI syndrome, there were 24 females and 19 males. The median age at onset was 3.9 years. The main clinical manifestations included anemia (100%), neutropenia (98%), cutaneous manifestations (74%), osteoarticular manifestations (72%), splenomegaly (70%), growth failure (57%), fever (51%), hepatomegaly (56%), and lymphadenopathy (39%). Systemic inflammation was described in all patients. Marked elevation of zinc and MRP 8/14 blood levels were observed in all tested patients. Response to treatment varied and no consistently effective therapy was identified. The most common therapeutic options were corticosteroids (N = 30), anakinra (N = 13), cyclosporine A (N = 11), canakinumab (N = 6), and anti-TNF (N = 14). Hematopoietic stem cell transplantation has been recently reported to be successful in five patients. Our review highlights the key characteristics of PAMI syndrome and the importance of considering this disease in the differential diagnosis of patients presenting with early-onset systemic inflammation and cytopenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Necrosis Factor InhibitorsNeutropeniaMaleDiagnosis, DifferentialMetal Metabolism, Inborn ErrorsFemaleCytoskeletal ProteinsHumansAdaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

E250KE257KHyperzincemia/HypercalprotectinemiaPAMI syndromePSTPIP1 geneautoinflammationcytopenia

Substanzen

Tumor Necrosis Factor InhibitorsPSTPIP1 protein, humanCytoskeletal ProteinsAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Pediatric Immuno-Rheumatology of Western Switzerland, Department Women-Mother-Child, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Pediatric Hematology-Oncology Unit, Division of Pediatrics, Department Women-Mother-Child, Lausanne University Hospital, 1011 Lausanne, Switzerland.
  • Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Medical Library, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, 45147 Essen, Germany.
  • Department of Applied Health Sciences, University of Applied Sciences Bochum, 44801 Bochum, Germany.

ORCID-Profile: Manel Mejbri, Cecile Jaques, Dirk Holzinger

Zitieren

APA

Mejbri, M., Renella, R., Candotti, F., Jaques, C., Holzinger, D., Hofer, M., & Theodoropoulou, K. (2023). PSTPIP1-Associated Myeloid-Related Proteinemia Inflammatory (PAMI) Syndrome: A Systematic Review. Genes, 14(8), 1655. https://doi.org/10.3390/genes14081655

Vancouver

Mejbri M, Renella R, Candotti F, Jaques C, Holzinger D, Hofer M, et al. PSTPIP1-Associated Myeloid-Related Proteinemia Inflammatory (PAMI) Syndrome: A Systematic Review. Genes. 2023;14(8):1655. doi:10.3390/genes14081655

BibTeX
@article{Mejbri2023,
  author = {Mejbri, Manel and Renella, Raffaele and Candotti, Fabio and Jaques, Cecile and Holzinger, Dirk and Hofer, Michael and Theodoropoulou, Katerina},
  title = {PSTPIP1-Associated Myeloid-Related Proteinemia Inflammatory (PAMI) Syndrome: A Systematic Review},
  journal = {Genes},
  year = {2023},
  volume = {14},
  number = {8},
  pages = {1655},
  doi = {10.3390/genes14081655}
}
Kostenlos starten →